JO
CCCC icon

John Overdeck’s C4 Therapeutics CCCC Stock Holding History

John Overdeck’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Buy
3,469,707
+434,073
+14% +$1.48M 0.01% 1184
2026
Q1 		$7.98M Buy
3,035,634
+1,526,031
+101% +$3.59M 0.01% 1582
2025
Q4 		$2.88M Buy
1,509,603
+674,877
+81% +$1.6M ﹤0.01% 2166
2025
Q3 		$1.85M Buy
834,726
+151,127
+22% +$363K ﹤0.01% 2180
2025
Q2 		$978K Buy
683,599
+168,996
+33% +$246K ﹤0.01% 2266
2025
Q1 		$823K Sell
514,603
-49,234
-9% -$147K ﹤0.01% 2287
2024
Q4 		$2.03M Sell
563,837
-264,653
-32% -$1.32M ﹤0.01% 1703
2024
Q3 		$4.72M Sell
828,490
-479,243
-37% -$2.88M 0.01% 1120
2024
Q2 		$6.04M Buy
1,307,733
+135,893
+12% +$810K 0.01% 927
2024
Q1 		$9.57M Buy
+1,171,840
New +$9.08M 0.02% 670
2023
Q4 		– Sell
-402,527
Closed -$749K – 3170
2023
Q3 		$749K Sell
402,527
-166,552
-29% -$508K ﹤0.01% 2088
2023
Q2 		$1.56M Buy
569,079
+305,815
+116% +$983K ﹤0.01% 1654
2023
Q1 		$827K Buy
263,264
+144,989
+123% +$854K ﹤0.01% 1966
2022
Q4 		$698K Sell
118,275
-77,484
-40% -$642K ﹤0.01% 1874
2022
Q3 		$1.72M Sell
195,759
-138,132
-41% -$1.43M 0.01% 1215
2022
Q2 		$2.52M Buy
333,891
+218,960
+191% +$1.93M 0.01% 1065
2022
Q1 		$2.79M Buy
+114,931
New +$2.79M 0.01% 1193
2021
Q4 		– Sell
-21,073
Closed -$942K – 4327
2021
Q3 		$942K Buy
21,073
+10,100
+92% +$433K ﹤0.01% 2672
2021
Q2 		$415K Buy
+10,973
New +$393K ﹤0.01% 3250

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's CCCC Position: Q2 2026 in Review

John Overdeck increased its C4 Therapeutics (CCCC) stake by 14% in Q2 2026, buying an estimated $1.48M and bringing the position to 3,469,707 shares worth $16.2M. The position accounts for 0.01% of the portfolio, ranked #1184.

John Overdeck first reported a position in CCCC in Q2 2021 and has held it in 19 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • John Overdeck held 3,469,707 shares of C4 Therapeutics worth $16.2M as of Q2 2026.
  • John Overdeck bought 434,073 C4 Therapeutics shares in Q2 2026, an estimated $1.48M.
  • C4 Therapeutics made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1184 holding.
  • John Overdeck first reported a position in C4 Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.